Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Table 4 Reasons for treatment discontinuation of patients with OS ≥24 versus < 24 months in the axitinib titration arm

Reason for treatment discontinuation, n (%)	OS ≥24 months n = 33^a	OS < 24 months n = 20^b
Objective progression or relapse	17 (52)	16 (80)
Adverse event	5 (15)	2 (10)
Death	1 (3)	1 (5)
Global deterioration of health status	0	1 (5)
Patient refusal to continue treatment for reason other than adverse event	1 (3)	0
Total	24 (73)	20 (100)

ISSN: 1471-2407